This is a paid press release. Contact the press release distributor directly with any enquiries.
Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates
Research and Markets
Wed, 15 July 2026 at 1:45 pm GMT+5:30
14 min read
Key opportunities include oral GLP-1 and next-generation incretin drugs, combination therapies, personalized metabolic treatments, gut hormone modulators, telehealth-enabled prescribing, and convenient non-injectable options for rising obesity care needs
Dublin, July 15, 2026 (GLOBE NEWSWIRE) — The “Oral Obesity Therapies Market Report 2026” has been added to ResearchAndMarkets.com’s offering
The Oral Obesity Therapies Market Global Report 2026 provides strategists, marketers, investors and senior executives with comprehensive intelligence on a rapidly expanding global healthcare market. Covering five years of historical data and ten years of forecasts, the report examines the forces expected to shape oral obesity treatment through 2036, including pharmaceutical innovation, regulatory change, consumer preferences, digital health adoption and evolving patient needs
The report evaluates oral obesity therapies market size, growth, segmentation, regional performance, competitive dynamics and investment potential. It identifies the largest and fastest-growing markets while assessing how economic conditions, demographic trends, healthcare expenditure and related pharmaceutical markets influence demand
Forecasts account for major market variables, including advances in artificial intelligence and automation, inflation, interest rates, trade tariffs, geopolitical conflicts and shifting regulatory frameworks. Expanded coverage of Taiwan and Southeast Asia also reflects supply chain realignment, manufacturing investment and the growing importance of these markets within the global pharmaceutical value chain
Strategic Market Intelligence
The research includes market characteristics, supply chain analysis, regulatory and investment landscapes, emerging trends, market attractiveness scoring, total addressable market analysis and company benchmarking. It also reviews digital transformation, automation, sustainability initiatives and AI-driven innovation, highlighting opportunities for businesses to strengthen market positioning and achieve competitive differentiation
Develop regional and country strategies using localized historical and forecast data
Identify high-growth oral obesity drug segments and investment opportunities
Assess market potential, competitive intensity, strategic fit and risk
Benchmark leading companies by market share, revenue, innovation and brand recognition
Evaluate customer demand through patient indication, application, sales channel and end-user analysis
Examine supplier relationships, raw materials and competitors across the value chain
Support presentations and strategic planning with reliable data, analysis and end-note sourcing
